NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt

Core Viewpoint - Nektar Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding patient enrollment compliance in its pivotal REZOLVE-AA clinical trial, which has raised concerns about the integrity of the trial results [1][4][6]. Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025, and December 15, 2025 [2]. - Nektar's shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, following the disclosure of enrollment violations in the REZOLVE-AA trial [3]. - Investors have until May 5, 2026, to seek lead plaintiff status in the lawsuit [3]. Group 2: Clinical Trial Enrollment Issues - The REZOLVE-AA trial required strict patient eligibility criteria, including a SALT score between 50 and 100, stable disease for at least six months, and completion of an eight-week washout period from prior medications [3]. - The lawsuit claims that Nektar failed to enforce these standards, resulting in the randomization of four ineligible patients, which constituted over 4% of the total 94 patients randomized [4][5]. - The trial's primary endpoint narrowly missed statistical significance when including the ineligible patients, with p-values of 0.186 and 0.121 for the two dosing arms [5]. Group 3: Management's Misrepresentation - Nektar management allegedly misled investors by claiming adherence to trial protocols while ineligible patients were enrolled [6]. - The complaint highlights a significant gap between Nektar's representations about its enrollment procedures and the actual practices at its trial sites [4]. - Joseph E. Levi, Esq. emphasized that shareholders deserve accurate information regarding the integrity of the clinical enrollment process [7].